SpecificityRUNX2 (Phospho-S340) Antibody detects endogenous levels of RUNX2 only when phosphorylated at S340
Immunogen TypePeptide-KLH
Immunogen DescriptionA synthesized peptide derived from human RUNX2 (Phospho-Ser340)
Alternative NamesAcute myeloid leukemia 3 protein antibody
Alpha subunit 1 antibody
AML3 antibody
CBF alpha 1 antibody
CBF-alpha-1 antibody
CBFA1 antibody
CCD antibody
CCD1 antibody
Cleidocranial dysplasia 1 antibody
Core binding factor antibody
Core binding factor runt domain alpha subunit 1 antibody
Core binding factor subunit alpha 1 antibody
Core-binding factor subunit alpha-1 antibody
MGC120022 antibody
MGC120023 antibody
Oncogene AML 3 antibody
Oncogene AML-3 antibody
OSF 2 antibody
OSF-2 antibody
OSF2 antibody
Osteoblast specific transcription factor 2 antibody
Osteoblast-specific transcription factor 2 antibody
OTTHUMP00000016533 antibody
PEA2 alpha A antibody
PEA2-alpha A antibody
PEA2aA antibody
PEBP2 alpha A antibody
PEBP2-alpha A antibody
PEBP2A1 antibody
PEBP2A2 antibody
PEBP2aA antibody
PEBP2aA1 antibody
Polyomavirus enhancer binding protein 2 alpha A subunit antibody
Polyomavirus enhancer-binding protein 2 alpha A subunit antibody
Runt domain antibody
Runt related transcription factor 2
Accession No.Swiss-Prot#:Q13950 NCBI Gene ID860
Calculated MW55-62
Concentration1.0mg mL
FormulationRabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+) pH 7.4 150mM NaCl 0.02% sodium azide and 50% glycerol.
StorageStore at -20˚C
Application Details
WB dilution:1:1000
Images
Western blot analysis RUNX2 (Phospho-Ser340) using HeLa whole cell lysates
Product Description
RUNX2 is a member of the RUNX family of transcription factors. It is involved in osteoblast differentiation and skeletal morphogenesis. RUNX2 regulates the transcription of various genes including osteopontin, bone sialoprotein, and osteocalcin via binding to the core site of the enhancers or promoters (1-3). RUNX2 is crucial for the maturation of osteoblasts and both intramembranous and endochondral ossification. Mutations in RUNX2 have been associated with the bone development disorder cleidocranial dysplasia (CCD) (4-6). RUNX2 is also abnormally expressed in various human cancers including prostate cancer and breast cancer. It plays an important role in migration, invasion, and bone metastasis of prostate and breast cancer cells (7-10).